SecBot SecBot
8-K ·Filed Aug 14, 2026

ZNTL

Zentalis Pharmaceuticals, Inc.
BEARISH
Impact 6/10
Horizondays Processed3mo ago SEC0001628280-26-057112
8-K context-dependent: Items 8.01
Actionable Insight ▼ Bearish

The substantial dilutive offering at a price near the current market cap signals the company is raising capital to extend its cash runway for clinical programs. Monitor for the stock's reaction to the dilution and any upcoming clinical data readouts that could justify the capital raise. The 60-day lock-up on insiders provides some near-term support, but the overhang from the offering will pressure the stock.

DirectionBearish
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$3.71
T+0 close · Aug 14, 2026 · via day close
Latest settled
−51.42%
T+60 · $1.80
Vs SPY
−48.47%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 17 $3.71entry
  2. T+1 · 3mo ago −0.67%α +0.00% · $3.68
  3. T+5 · 3mo ago +1.48%α +2.68% · $3.76
  4. T+20 · 2mo ago −15.52%α −13.54% · $3.13
  5. T+60 · 7d ago −51.42%α −48.47% · $1.80
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Zentalis Pharmaceuticals priced a public offering of 23,000,000 shares of common stock at $3.50 per share, with an underwriter option for an additional 3,450,000 shares. The company expects net proceeds of approximately $75.1 million to fund clinical trials, manufacturing, and general corporate purposes. This dilutive offering represents a significant portion of the company's pre-offering market cap of $297M.

Key Facts

  • 23,000,000 shares of common stock offered at $3.50 per share
  • Underwriters have a 30-day option to purchase up to an additional 3,450,000 shares
  • Estimated net proceeds of approximately $75.1 million
  • Closing expected August 17, 2026
  • Proceeds to fund clinical trials, preclinical studies, regulatory filings, manufacturing, and companion diagnostic
  • Underwriting agreement dated August 13, 2026
  • Shares offered under effective shelf registration statement on Form S-3 (File No. 333-286122)
  • Underwriters include TD Securities, Guggenheim Securities, Oppenheimer, H.C. Wainwright, and Rodman Renshaw

Financial Impact

Dilutive offering of 23M shares (plus up to 3.45M additional) at $3.50/share, raising ~$75.1M net. At a $297M market cap, this represents ~7.9% dilution from the firm shares alone, or ~9.1% if the overallotment is fully exercised.

dilutioncashshare count

Risk Factors

  • Significant dilution to existing shareholders
  • Proceeds used for clinical trials with binary outcomes
  • Potential for further capital raises if clinical programs require additional funding
  • Stock price may decline as new shares enter the market

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
63% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-057112
Exhibit: exhibit51-8xkaugust2026.htm0001628280-26-057112
Document: zntl-20260813.htm0001628280-26-057112
Document: 0001628280-26-057112-index-headers.html0001628280-26-057112
Document: 0001628280-26-057112-index.html0001628280-26-057112
Document: 0001628280-26-057112.txt0001628280-26-057112

Track record

18 reports on ZNTL

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +51.12% at T+60 after the Aug 13, 2026 report. 5 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 4/10 Entry $1.62 Now $1.60 −1.23% settles Feb 12
  2. Nov 9, 20267d ago 8-K Bearish 5/10 Entry $1.80 Now $1.60 +11.11% settles Feb 8
  3. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $2.06 Now $1.60 −22.33% settles Jan 26
  4. Oct 18, 202629d ago Press Release Bullish 7/10 Entry $2.30 Now $1.60 −30.43% settles Jan 14
  5. Oct 1, 20266w ago Press Release Neutral 2/10 Entry $2.52 Now $1.60 −36.51% settles Dec 29
  6. Aug 14, 202613w ago 8-K Bearish 6/10 Viewing Entry $3.71 to $1.80 Now $1.60 +56.82% ▲ +51.42% +48.47% vs SPY
  7. Aug 13, 202613w ago Press Release Bearish 6/10 Entry $3.56 to $1.74 Now $1.60 +55.06% ▲ +51.12% +48.08% vs SPY
  8. Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $3.75 to $4.03 Now $1.60 −57.33% ▲ +7.47% +4.20% vs SPY
  9. Jun 1, 202624w ago Press Release Neutral 2/10 Entry $3.95 to $3.89 Now $1.60 −59.49% ▼ −1.52% −2.64% vs SPY
  10. May 21, 202625w ago Press Release Bullish 6/10 Entry $4.06 to $3.68 Now $1.60 −60.59% ▼ −9.36% −12.55% vs SPY
Showing 10 of 18

US Market Status

Market Closed · Opens in 7h 30m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 14, 2026